Article
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
All News
Article
Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.
Article
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Article
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
Article
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
Dr. John Cush
Tweet
Pre-Clinical RA - Clinical Trial Outcomes
https://t.co/EIG1eam31h https://t.co/6rYcGmgJG5
Dr. John Cush
Tweet
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Dr. John Cush
Tweet
Biologics Keep Early RA in Check for at Least One Year
Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.
https://t.co/FBFX53lZfp https://t.co/l1RapKWlFk
Dr. John Cush
Tweet
ICYMI: RA Disease Activity and Alcohol Use
https://t.co/tXuAJ4GRl4 https://t.co/3ieVw8BcIs
Dr. John Cush
Tweet
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
https://t.co/o56m9WumiC. https://t.co/GHe1RprDnk
Dr. John Cush
Tweet
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb
Dr. John Cush
Tweet
Upadacitinib Outcomes in High Risk RA Patients
A safety analysis of six phase III SELECT trials showed that higher-risk RA patients had an increased risk of MACE, malignancy (excluding NMSC) and VTE regardless of being treated with either UPA or ADA.
https://t.co/7JXntIV09K https://t.co/CthPcu2Ohs
Dr. John Cush
Tweet
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/NubTu8mGq4 https://t.co/OQSIpHgLyn
Dr. John Cush
Tweet
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Dr. John Cush
Tweet
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Dr. John Cush
Tweet
RT @drdavidliew : Tapering pred in RA - this just rings true from everyday clinic life.
Some patients just seem to hit a wall at PNL 2.5. Sometimes it’s GC withdrawal arthralgias/tertiary adrenal insufficiency, but often it’s genuine inflammation.
I still wonder why?
POS0050
Dr. John Cush
Tweet
RT @AurelieRheumo : The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8)
Use of TNFi & orthopedic implants associated w/ OAI risk
Mortality however similar in RA and non RA groups
#EULAR23 POS0033
Dr. John Cush
Tweet
RT @drdavidliew : Men trying to conceive were prev told to avoid MTX. Another myth busted
Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues!
OP0224 #EULAR2023 https://t.co/i4WGmoWOwU)
Dr. John Cush
Tweet
RT @Yuz6Yusof : #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest
Dr. John Cush
Tweet
RT @Janetbirdope :What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly -if resolution, still more MRI + vs neg. #EULAR2023 POS319. Diff patterns of progression